FORMULA-509:根治性前列腺切除术后挽救性放疗联合6个月GnRH激动剂及比卡鲁胺或阿比特龙+泼尼松+阿帕他胺的多中心随机试验
FORMULA-509试验纳入345例根治性前列腺切除术后PSA≥0.1 ng/ml且具有高危因素的患者,随机接受挽救性放疗联合6个月GnRH激动剂及比卡鲁胺或阿比特龙+泼尼松+阿帕他胺治疗。中位随访34个月,总体人群无PSA进展生存期(PFS)未达预设显著性水平(HR 0.71,90%CI 0.49-1.03;p=0.063),但预设亚组分析显示PSA>0.5 ng/ml患者中阿比特龙+泼尼松+阿帕他胺较比卡鲁胺显著改善PFS和转移无生存期(MFS)。
要点
- 总体人群PFS未达预设显著性(HR 0.71,90%CI 0.49-1.03;p=0.063)。
- PSA>0.5 ng/ml亚组中阿比特龙+泼尼松+阿帕他胺显著改善PFS(HR 0.50,95%CI 0.27-0.95;p=0.030)。
- 该亚组MFS亦显著改善(HR 0.32,95%CI 0.13-0.84;p=0.014)。
核心结论
- 总体人群未显示阿比特龙+泼尼松+阿帕他胺较比卡鲁胺在PFS上的获益。
- 预设亚组PSA>0.5 ng/ml中,阿比特龙+泼尼松+阿帕他胺较比卡鲁胺改善PFS和MFS。
研究设计与样本
- 多中心随机试验FORMULA-509(NCT03141671),纳入345例根治性前列腺切除术后PSA≥0.1 ng/ml且具有高危因素的患者。
- 患者接受挽救性放疗联合6个月GnRH激动剂,随机分配至比卡鲁胺(50 mg)或阿比特龙+泼尼松(1000 mg/5 mg)+阿帕他胺(240 mg)每日一次。
- 主要终点为PSA无进展生存期(PFS),次要终点为常规影像学转移无生存期(MFS)。
- 按PSA(>0.5 vs ≤0.5 ng/ml)和pN状态(pN0 vs pN1)分层。
主要发现
- 中位随访34个月。
- 总体人群PFS:阿比特龙+泼尼松+阿帕他胺 vs 比卡鲁胺 HR 0.71(90%CI 0.49-1.03;分层单侧log-rank p=0.063),3年PFS率分别为74.9% vs 68.5%。
- 总体人群MFS:HR 0.57(90%CI 0.33-1.01;分层单侧p=0.050),3年MFS率分别为90.6% vs 87.2%。
- PSA>0.5 ng/ml亚组:PFS HR 0.50(95%CI 0.27-0.95;双侧p=0.030),3年PFS率67.2% vs 46.8%;MFS HR 0.32(95%CI 0.13-0.84;双侧p=0.014),3年MFS率84.3% vs 66.1%。
- 不良事件与已知安全性一致,阿比特龙+泼尼松+阿帕他胺组皮疹和高血压更常见。
关键数值与推荐
- 分层因素:PSA>0.5 vs ≤0.5 ng/ml;pN0 vs pN1。
- 预设亚组分析:PSA>0.5 ng/ml患者中阿比特龙+泼尼松+阿帕他胺较比卡鲁胺改善PFS(HR 0.50,95%CI 0.27-0.95;p=0.030)和MFS(HR 0.32,95%CI 0.13-0.84;p=0.014)。
临床怎么用
- 对于根治性前列腺切除术后PSA≥0.1 ng/ml且具有高危因素、拟接受挽救性放疗联合6个月GnRH激动剂的患者,总体人群暂不支持常规使用阿比特龙+泼尼松+阿帕他胺替代比卡鲁胺。
- PSA>0.5 ng/ml的患者可能从阿比特龙+泼尼松+阿帕他胺治疗中获得PFS和MFS获益,需结合个体情况评估。
- 应用阿比特龙+泼尼松+阿帕他胺时需注意皮疹和高血压等不良反应。
局限性
- 中位随访34个月,事件数可能有限。
- 总体人群主要终点未达预设显著性水平,亚组分析结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: For patients with detectable prostate-specific antigen (PSA) after radical prostatectomy, 6 mo of a GNRH agonist with salvage radiotherapy (sRT) is a standard treatment option. METHODS: FORMULA-509 (NCT03141671) enrolled 345 patients with PSA ≥0.1 ng/ml and high-risk features from November 24, 2017 to March 25, 2020. Patients received sRT plus 6 mo of a GNRH agonist and randomization to bicalutamide (50 mg) or abiraterone acetate + prednisone (AAP; 1000 mg/5 mg) + apalutamide (240 mg) QD. The primary endpoint was PSA progression-free survival (PFS). A secondary endpoint was metastasis-free survival (MFS) on conventional imaging. Stratification was by PSA (>0.5 vs ≤0.5 ng/ml) and pN status (pN0 vs pN1). KEY FINDINGS AND LIMITATIONS: Median follow-up was 34 mo. AAP + apalutamide did not reach the prespecified significance level for PFS benefit in comparison to bicalutamide (hazard ratio [HR] 0.71. 90% confidence interval [CI] 0.49-1.03; stratified one-sided log-rank p = 0.063), with 3-yr PFS rates of 68.5% with bicalutamide versus 74.9% with AAP + apalutamide. The HR for MFS was 0.57 (90% CI 0.33-1.01; stratified one-sided p = 0.050) and the 3-yr MFS rates were 87.2% with bicalutamide versus 90.6% with AAP + apalutamide. A preplanned analysis by stratification factors revealed that for patients with PSA >0.5 ng/ml, AAP + apalutamide was associated with superior PFS (HR 0.50, 95% CI 0.27-0.95; 2-sided p = 0.030; 3-yr PFS 46.8% with bicalutamide vs 67.2% with AAP + apalutamide) and MFS (HR 0.32, 95% CI 0.13-0.84; 2-sided p = 0.014; 3-yr MFS 66.1% with bicalutamide vs 84.3% with AAP + apalutamide). Adverse events were consistent with the known safety profiles of the study agents, with more frequent rash and hypertension in the AAP + apalutamide arm. CONCLUSIONS AND CLINICAL IMPLICATIONS: This study did not reveal a benefit for the overall population, but addition of AAP + apalutamide (vs bicalutamide) to sRT and ADT improved PFS and MFS in the prespecified subgroup with PSA >0.5 ng/ml.
引用
- Nguyen PL, Kollmeier MA, Rathkopf DE, et al. FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide. Eur Urol. 2026. PMID: 41672869. doi:10.1016/j.eururo.2025.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。